Ziprasidone (US brand name Geodon® and generic) is a second-generation (“atypical”) antipsychotic.

FDA-approved indications

A. As an oral formulation
1. Schizophrenia
2. Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder
3. Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate

B. As an intramuscular injection
Acute treatment of agitation in schizophrenic patients

Dosage

Schizophrenia
Initial: 20 mg twice daily
Dose may be adjusted at an interval of 2 or more days
Maximum: 80 mg twice daily

Acute treatment of manic/mixed episodes of bipolar I disorder
Initial: 40 mg twice daily
Increase to 60 mg or 80 mg twice daily on day 2
Maximum: 80 mg twice daily

Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate
40–80 mg twice daily

Acute treatment of agitation associated with schizophrenia (intramuscular administration)
10 mg every 2 hours or 20 mg every 4 hours, up to a maximum of 40 mg/day

Dosage forms and strengths

Capsules (Geodon® and generic): 20 mg, 40 mg, 60 mg, and 80 mg
Intramuscular injection (Geodon®): 20 mg/mL single-use vials

Please refer to Prescribing Information (see link below) for complete discussion of dosage, administration, warnings and precautions, contraindications, etc.